Back

Impact of anemia on clinical outcomes of active cancer patients with low-risk pulmonary embolism receiving rivaroxaban: insight from the ONCO PE trial

30 August 2025 (12:20 - 12:30)
Organised by: Logo
Congress Presentation Part of: Anticipating risk to protect the heart during cancer treatment Diagnosis and Management of Cardiovascular Disease in Patients with Cancer ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Ryuki Chatani

Kurashiki Central Hospital, Kurashiki (Japan)

5 More presentations in this session

Presentation thumbnail
Use of direct oral anticoagulants in patients with atrial fibrillation and cancer: a subanalysis of the nationwide Italian START registry
Doctor V. Cormaci (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Atorvastatin and left ventricular global longitudinal strain during anthracycline-based chemotherapy
Doctor V. Juhasz (Boston, US)
Abstract Slides Video
Presentation thumbnail
Pathogenic variants in titin predispose to anthracycline cardiotoxicity: insights from an hiPSC-CM model
Doctor H. Boen (Edegem, BE)
Abstract Slides Video
Presentation thumbnail
Cardiovascular adverse events in primary lung cancer patients treated with immune checkpoint inhibitors: a nationwide database study
Doctor T. Isawa (Sendai, JP)
Abstract Slides Video
Presentation thumbnail
Improved risk stratification with SCORE2 on top of HFA-ICOS in cancer patients without previous cardiovascular disease
Mrs M. Gynnild (Trondheim, NO)
Abstract Slides Video

Access the full session

Session thumbnail
Anticipating risk to protect the heart during cancer treatment
Video

The Event

Event poster

ESC Congress 2025

30 August 2025 12:20 CET
You may be interested in
thumbnail
Congress Session
Anticipating risk to protect the heart during cancer treatment
thumbnail
Congress Session
Rethinking cancer-associated venous thromboembolism (VTE): integrating evidence into practice
thumbnail
Congress Presentation
Efficacy and safety of prolonged rivaroxaban treatment for high-bleeding risk cancer patients with acute low-risk pulmonary embolism: a post-hoc subgroup analysis of the ONCO PE trial

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources